.Regeneron is actually back along with long-lasting follow-up for its own LAG-3 prevention as well a...
.AstraZeneca has shared an early look at the functionality of its own in-house antibody-drug conjuga...
.After declaring a period 3 launch based upon favorable midstage outcomes, iTeos and GSK are eventua...
.The FDA should be even more available and collective to release a rise in commendations of uncommon...
.It's an uncommonly busy Friday for biotech IPOs, with Zenas BioPharma, MBX and also Bicara Rehabs a...
.Atea Pharmaceuticals' antiviral has actually fallen short an additional COVID-19 trial, yet the bio...
.Neurocrine Biosciences' schizophrenia plan pivot has failed. The biotech was actually not able to r...
.Sanofi has created a late entry to the radioligand gathering, paying 100 thousand euros ($ 110 mill...
.After F2G's 1st attempt to acquire a brand-new lesson of antifungal to market was thwarted by the F...
.Moderna has promised to reduce R&D costs through $1.1 billion by 2027. The choice to shrink the ...